Treatment of malignant ascites

Current Treatment Options in Oncology

Volumn 9, Issue 2-3, 2008, Pages 215-233

  Chung, Michael ^a   Kozuch, Peter ^a  

^a BETH ISRAEL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; BATIMASTAT; BLEOMYCIN; CATUMAXOMAB; CHLORMETHINE; CISPLATIN; DIURETIC AGENT; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GOLD; INTERLEUKIN 2; MATRIX METALLOPROTEINASE INHIBITOR; MITOMYCIN C; MITOXANTRONE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2G3; OCTREOTIDE; OXALIPLATIN; PACLITAXEL; PICIBANIL; PLACEBO; SPIRONOLACTONE; THIOTEPA; TRIAMCINOLONE HEXACETONIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABDOMINAL CANCER; ABDOMINAL DISCOMFORT; ABDOMINAL DISTENSION; ABDOMINAL PAIN; ANEMIA; ANOREXIA; ARTICLE; BACTERIAL PERITONITIS; CANCER CHEMOTHERAPY; CHILL; CLINICAL PROTOCOL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CYTOREDUCTIVE SURGERY; DIAGNOSTIC IMAGING; DIAGNOSTIC PROCEDURE; DIARRHEA; DISEASE ASSOCIATION; DISEASE RESISTANCE; DRUG CYTOTOXICITY; DRUG FATALITY; DRUG FEVER; DRUG HYPERSENSITIVITY; DYSPEPSIA; EDEMA; ERYTHEMA; FATIGUE; FEBRILE NEUTROPENIA; FLU LIKE SYNDROME; HEMATOLOGIC DISEASE; HEMATOLOGIC SUPPRESSION; HEPATOBILIARY SYSTEM CANCER; HERPES ZOSTER; HUMAN; HYPOTENSION; ILEUS; INFECTION; INTESTINE OBSTRUCTION; LEUKOPENIA; LUNG DISEASE; LUNG EMBOLISM; MALAISE; MALIGNANT ASCITES; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE ORGAN FAILURE; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; ORTHOSTATIC HYPOTENSION; PAIN; PARACENTESIS; PATHOPHYSIOLOGY; PERITONEUM; PERITONEUM VEIN SHUNT; PHYSICAL EXAMINATION; PLATELET TOXICITY; PRACTICE GUIDELINE; SEPSIS; SEPTIC SHOCK; SMALL INTESTINE PERFORATION; SURGICAL DRAINAGE; THORAX PAIN; THROMBOCYTOPENIA; VOMITING;

ANTIBODIES, MONOCLONAL; ASCITES; CLINICAL TRIALS AS TOPIC; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; IMMUNOTHERAPY; MALE; MATRIX METALLOPROTEINASES; MEDICAL ONCOLOGY; PERITONEAL NEOPLASMS; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 58149085275     PISSN: 15272729     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11864-008-0068-y     Document Type: Article

References (80)

1. Runyon, B.A., (1994) Care of patients with ascites. N Engl J Med 330(5):337-42. doi: 10.1056/NEJM199402033300508.
2. Ayantunde, A.A. and S.L. Parsons. Pattern and prognostic factors in patients with malignant ascites: A retrospective study. Ann Oncol 2007; 18(5):945-9. doi: 10.1093/annonc/mdl499.
3. Spratt, J.S., et al., (1996) Peritoneal carcinomatosis: Anatomy, physiology, diagnosis, management. Curr Probl Cancer 10:558-84.
4. Heuser, L.S. and FN. Miller. (1986) Differential macromolecular leakage from the vasculature of tumors. Cancer 57(3):461-4. doi:10.1002/ 1097-0142(19860201)57:3<461::AID-CNCR2820570310>3.0.CO;2-6.
5. Holm-Nielsen P: Pathogenesis of ascites in peritoneal carcinomatosis. Acta Pathol Microbiol Scand 1953, 33(1):10-21
6. Enck, R.E., (2002) Malignant ascites. Am J Hosp Palliat Care 19(1):7-8. doi: 10.1177/104990910201900101.
7. Smith, E.M. and G.C. Jayson, (2003) The current and future management of malignant ascites. Clin Oncol (R Coll Radiol) 15(2):59-72. doi: 10.1053/ clon.2002.0135.
8. Cardozo, P.L., (1966) A critical evaluation of 3000 cytologic analysis of pleural fluid, ascitic fluid and pericardial fluid. Acta Cytol 10:455-60.
9. DiBonito, L., et al. (1993) The positive peritoneal effusion A retrospective study of cytopathologic diagnoses with autopsy confirmation. Acta Cytol 37(4):483-8.
10. Parsons, S.L., M.W. Lang, and R.J. Steele, (1996) Malignant ascites: A 2-year review from a teaching hospital. Eur J Surg Oncol 22(3):237-9. doi: 10.1016/S0748-7983(96)80009-6.
11. Runyon, B.A., J.C. Hoefs, and T.R. Morgan (1988) Ascitic fluid analysis in malignancy-related ascites. Hepatology 8(5):1104-9. doi: 10.1002/ hep.1840080521.
12. Runyon, B.A., et al. (1992) The serum-ascites albumin gradient is superior to the exudate-transudate concept in the differential diagnosis of ascites. Ann Intern Med 117(3):215-20.
13. Sharma, S. and D. Walsh (1995) Management of symptomatic malignant ascites with diuretics: Two case reports and a review of the literature. J Pain Symptom Manage 10(3):237-42. doi: 10.1016/0885-3924(94)00129-9.
14. Mackey JR, VeDner PM: Malignant ascites: demographics, therapeutic efficacy and predictors of survival. Can J Oncol 1996, 6(2): 474-480
15. Becker, G., D. Galandi, and H.E. Blum (2006) Malignant ascites: systematic review and guideline for treatment. Eur J Cancer 42 (5):589-97. doi: 10.1016/j.ejca.2005.11.018.
16. Pockros, P.J., et al. (1992) Mobilization of malignant ascites with diuretics is dependent on ascitic fluid characteristics. Gastroenterology 103(4):1302-6.
17. Fischer DS: Abdominal paracentesis for malignant ascites. Arch Intern Med 1979, 139(2):235. doi: 10.1001/archinte.139.2.235.
18. Gines, P., et al. (2004) Management of cirrhosis and ascites. N Engl J Med 350(16):1646-54. doi: 10.1056/NEJMra035021.
19. Richard, H.M., 3rd, et al., (2001) Pleurx tunneled catheter in the management of malignant ascites. J Vasc Interv Radiol 12(3):373-5. doi: 10.1016/S1051-0443(07)61919-8.
20. Belfort, M.A., et al. (1990) A new approach to the management of malignant ascites; a permanently implanted abdominal drain. Eur J Surg Oncol 16(1):47-53.
21. Lee, CW., G. Bociek, and W. Faught (1998) A survey of practice in management of malignant ascites. J Pain Symptom Manage 16(2):96-101. doi: 10.1016/S0885-3924(98)00037-2.
22. Rosenberg, S., et al. (2004) Comparison of percutaneous management techniques for recurrent malignant ascites. J Vasc Interv Radiol 15(10):1129-31.
23. Adam, R.A. and Y.G. Adam (2004) Malignant ascites: Past, present, and future. J Am Coll Surg 198(6):999-1011. doi: 10.1016/ j.jamcollsurg.2004.01.035.
24. Courtney, A.L., A.A. Nemcek, and S.M. Rosenberg (2006) Efficacy and Safety of the Pleurx Catheter When Used to Treat Recurrent Malignant Ascites (abstract). JVIR 17(2):S25.
25. Lee, A., T.N. Lau, and K.Y. Yeong (2000) Indwelling catheters for the management of malignant ascites. Support Care Cancer 8(6):493-9.
26. Seike, M., I. Maetani, and Y. Sakai (2007) Treatment of malignant ascites in patients with advanced cancer: Peritoneovenous shunt versus paracentesis. J Gastroenterol Hepatol 22(12):2161-6. doi: 10.1111/ j.1440-1746.2006.04793.x.
27. Gough, I.R. (1984) Control of malignant ascites by peritoneovenous shunting. Cancer 54(10):2226-30. doi:10.1002/ 1097-0142(19841115)54:10<2226::AID-CNCR2820541026>3.0.CO;2-7.
28. Cheung, D.K. and J.H. Raaf (1982) Selection of patients with malignant ascites for a peritoneovenous shunt. Cancer 50(6):1204-9. doi:10.1002/ 1097-0142(19820915)50:6<1204::AID-CNCR2820500631>3.0.CO;2-W.
29. Schumacher, D.L., T.J. Saclarides, and E.D. Staren (1994) Peritoneovenous shunts for palliation of the patient with malignant ascites. Ann Surg Oncol 1(5):378-81. doi: 10.1007/BF02303809.
30. Rosenshein, N., et al. (1978) The effect of volume on the distribution of substances instilled into the peritoneal cavity. Gynecol Oncol 6(1):106-10. doi: 10.1016/0090-8258(78)90010-0.
31. Weisberger, A.S., B. Levine, and J.P. Storaasli (1955) Use of nitrogen mustard in treatment of serous effusions of neoplastic origin. J Am Med Assoc 159(18):1704-7.
32. Appelqvist, P., et al. (1982) On the treatment and prognosis of malignant ascites: Is the survival time determined when the abdominal paracentesis is needed? J Surg Oncol 20(4):238-42. doi: 10.1002/ jso.2930200411.
33. Ostrowski, M.J. (1986) An assessment of the long-term results of controlling the reaccumulation of malignant effusions using intracavity bleomycin. Cancer 57(4):721-7. doi:10.1002/ 1097-0142(19860215)57:4<721::AID-CNCR2820570407>3.0.CO;2-5.
34. Link KH, et al.: Intraperitoneal chemotherapy with mitoxantrone in malignant ascites. Surg Oncol Clin N Am 2003, 12(3):865-872, xvi-xvii. doi: 10.1016/S1055-3207(03)00050-4.
35. Maiche, A.G., (1994) Management of peritoneal effusions with intracavitary mitoxantrone or bleomycin. Anticancer Drugs 5(3):305-8. doi: 10.1097/00001813-199406000-00007.
36. Schilsky, R.L., et al. (1990) Phase I clinical and pharmacologic study of intraperitoneal cisplatin and fluorouracil in patients with advanced intraabdominal cancer. J Clin Oncol 8(12):2054-61.
37. Markman, M. and D. Kelsen (1992) Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma. J Cancer Res Clin Oncol 118(7):547-50. doi: 10.1007/ BF01225271.
38. Oh, S.Y., et al. (2007) A Phase II study of oxaliplatin with low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) for gastric cancer patients with malignant ascites. Jpn J Clin Oncol 37(12):930-5. doi: 10.1093/jjco/hym131.
39. Los, G., et al. (1992) A rationale for carboplatin treatment and abdominal hyperthermia in cancers restricted to the peritoneal cavity. Cancer Res 52(5):1252-8.
40. Verwaal, V.J., et al., (2003) Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 21(20):3737-43. doi: 10.1200/ JCO.2003.04.187.
41. Loggie, BW., et al. (2000) Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for disseminated peritoneal cancer of gastrointestinal origin. Am Surg 66(6):561-8.
42. Loggie, BW., et al. (1997) Treatment and prevention of malignant ascites associated with disseminated intraperitoneal malignancies by aggressive combined-modality therapy. Am Surg 63(2):137-43.
43. Loggie, BW., et al. (2001) Prospective trial for the treatment of malignant peritoneal mesothelioma. Am Surg 67(10):999-1003.
44. Bezwoda, W.R., L. Seymour, and R. Dansey (1989) Intraperitoneal recombinant interferon-alpha 2b for recurrent malignant ascites due to ovarian cancer. Cancer 64(5):1029-33. doi:10.1002/ 1097-0142(19890901)64:5<1029::AID-CNCR2820640511>3.0.CO;2-#.
45. Sartori, S., et al. (2001) Evaluation of a standardized protocol of intracavitary recombinant interferon alpha-2b in the palliative treatment of malignant peritoneal effusions A prospective pilot study. Oncology 61(3):192-6. doi: 10.1159/000055374.
46. Stuart, G.C., et al. (1993) Intraperitoneal interferon in the management of malignant ascites. Cancer 71(6):2027-30. doi:10.1002/ 1097-0142(19930315)71:6<2027::AID-CNCR2820710617>3.0.CO;2-C.
47. Gebbia, N., et al. (1994) Intracavitary treatment of malignant pleural and peritoneal effusions in cancer patients. Anticancer Res 14(2B):739-45.
48. Gebbia, V., et al. (1991) Intracavitary beta-interferon for the management of pleural and/or abdominal effusions in patients with advanced cancer refractory to chemotherapy. In Vivo 5(6):579-81.
49. Hirte, HW., et al. (1997) A randomized trial of paracentesis plus intraperitoneal tumor necrosis factor-alpha versus paracentesis alone in patients with symptomatic ascites from recurrent ovarian carcinoma. Gynecol Oncol 64(1):80-7. doi: 10.1006/gyno.1996.4529.
50. Einhorn, N., et al., (1982) Human leukocyte interferon therapy for advanced ovarian carcinoma. Am J Clin Oncol 5(2):167-72. doi: 10.1097/ 00000421-198204000-00064.
51. Räth, U., et al. (1991) Effect of intraperitoneal recombinant human tumour necrosis factor alpha on malignant ascites. Eur J Cancer 27(2):121-5.
52. Currie, J.L., et al. 1983 Intracavitary Corynebacterium parvum for treatment of malignant effusions. Gynecol Oncol 16(1):6-14. doi: 10.1016/ 0090-8258(83)90002-1.
53. Katano M, Torisu M: New approach to management of malignant ascites with a streptococcal preparation, OK-432. II. Intraperitoneal inflammatory cell-mediated tumor cell destruction. Surgery 1983, 93(3): 365-373
54. Torisu, M., et al. (1983) New approach to management of malignant ascites with a streptococcal preparation, OK-432 I Improvement of host immunity and prolongation of survival. Surgery 93(3):357-64.
55. Yamaguchi, Y., et al. (2003) Locoregional immunotherapy of malignant effusion from colorectal cancer using the streptococcal preparation OK-432 plus interleukin-2: Induction of autologous tumor-reactive CD4 + Th1 killer lymphocytes. Br J Cancer 89(10):1876-84. doi: 10.1038/ sj.bjc.6601379.
56. Katano, M. and T. Morisaki (1998) The past, the present and future of the OK-432 therapy for patients with malignant effusions. Anticancer Res 18(5D):3917-25.
57. Buckman, R., et al. (1992) Intraperitoneal therapy of malignant ascites associated with carcinoma of ovary and breast using radioiodinated monoclonal antibody 2G3. Gynecol Oncol 47(1):102-9. doi: 10.1016/ 0090-8258(92)90084-V.
58. Burges, A., et al. (2007) Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: A phase I/II study. Clin Cancer Res 13(13):3899-905. doi: 10.1158/1078-0432.CCR-06-2769.
59. Parsons SL, et al.: Treatment of ovarian cancer patients with malignant ascites using the trifunctional antibody catumaxomab: Results of a phase II/III study. J Clin Oncol 2007, 25(18S): 5520.
60. Krueger CM, et al.: Intraoperative, adjuvant treatment of gastric cancer with the trifunctional antibody catumaxomab compared to surgery alone: A phase II study. J Clin Oncol 2008 (May 20 suppl; abstr 15529).
61. Mackey, J.R., et al. (2000) A phase II trial of triamcinolone hexacetanide for symptomatic recurrent malignant ascites. J Pain Symptom Manage 19(3):193-9. doi: 10.1016/S0885-3924(00)00106-8.
62. Dybicki J, Balchum OJ, Meneely GR: Treatment of pleural and peritoneal effusion with intracavitary colloidal radiogold (Au 198). Arch Intern Med 1959, 104:802-815.
63. Ariel IM, Oropeza R, Pack GT: Intracavitary administration of radioactive isotopes in the control of effusions due to cancer. Results in 267 patients. Cancer 1966, 19(8):1096-1102. doi:10.1002/ 1097-0142(196608)19:8<1096::AID-CNCR2820190808>3.0.CO;2-N.
64. Jacobs, M.L. (1958) Radioactive colloidal chromic phosphate to control pleural effusion and ascites. J Am Med Assoc 166(6):597-9.
65. Card, R.Y., D.R. Cole, and U.K. Henschke (1960) Summary of ten years of the use of radioactive colloids in intracavitary therapy. J Nucl Med 1:195-8.
66. Taylor, A., Jr., et al. (1975) Loculation as a contraindication intracavitary 32P-chromic phosphate therapy. J Nucl Med 16(4):318-9.
67. National Cancer Institute: Phase III Randomized Study of Octreotide in Patients With Cancer-Related Symptomatic Malignant Ascites, protocol summary [cited June 20, 2008. http://www.cancer.gov/clinicaltrials/ NCCTG-N04C2].
68. Luo, J.C., M. Toyoda, and M. Shibuya (1998) Differential inhibition of fluid accumulation and tumor growth in two mouse ascites tumors by an antivascular endothelial growth factor/permeability factor neutralizing antibody. Cancer Res 58(12):2594-600.
69. Yukita, A., et al. (2000) Suppression of ascites formation and re-accumulation associated with human ovarian cancer by an anti-VPF monoclonal antibody in vivo. Anticancer Res 20(1A):155-60.
70. Verheul, H.M., et al. (2000) Targeting vascular endothelial growth factor blockade: Ascites and pleural effusion formation. Oncologist 5(Suppl 1):45-50. doi: 10.1634/theoncologist.5-suppl_1-45.
71. Low, J.A., et al. (1996) The matrix metalloproteinase inhibitor batimastat (BB-94) retards human breast cancer solid tumor growth but not ascites formation in nude mice. Clin Cancer Res 2(7):1207-14.
72. Yip, D., et al. (1999) Matrix metalloproteinase inhibitors: Applications in oncology. Invest New Drugs 17(4):387-99. doi: 10.1023/A:1006386406584.
73. Beattie, G.J. and J.F. Smyth (1998) Phase I study of intraperitoneal metalloproteinase inhibitor BB94 in patients with malignant ascites. Clin Cancer Res 4(8):1899-902.
74. Parsons, S.L., S.A. Watson, and R.J. Steele (1997) Phase I/II trial of batimastat, a matrix metalloproteinase inhibitor, in patients with malignant ascites. Eur J Surg Oncol 23(6):526-31. doi: 10.1016/ S0748-7983(97)93077-8.
75. Cairns, W. and R. Malone (1999) Octreotide as an agent for the relief of malignant ascites in palliative care patients. Palliat Med 13(5):429-30. doi: 10.1191/026921699677473561.
76. Mincher, L., et al. (2005) The successful treatment of chylous effusions in malignant disease with octreotide. Clin Oncol (R Coll Radiol) 17(2):118-21. doi: 10.1016/j.clon.2004.06.016.
77. Gilly, FN., et al. (1992) Treatment of malignant peritoneal effusion in digestive and ovarian cancer. Med Oncol Tumor Pharmacother 9(4):177-81.
78. François Y, et al.: Intraperitoneal chemo-hyperthermia with mitomycin C in cancer of the stomach with peritoneal carcinosis. J Chir (Paris) 1997, 134(5-6):237-242.
79. Garofalo, A., et al. (2006) Laparoscopic intraperitoneal hyperthermic chemotherapy for palliation of debilitating malignant ascites. Eur J Surg Oncol 32(6):682-5. doi: 10.1016/j.ejso.2006.03.014.
80. Kusano H, et al.: Continuous hyperthermic peritoneal perfusion (CHPP) for prevention or treatment of peritoneal dissemination. Gan To Kagaku Ryoho 1993, 20(11):1622-1625